An interventional study of Collectio nof blood in Antiphospholipid Syndrome, sponsored by CHU de Reims. Recruiting at 1 site in France. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-11-25.
Sponsored by CHU de Reims · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Antiphospholipid Syndrome with a site in France — 11 open to participants now, 11 under way, 1 of them phase 3. Antiphospholipid Syndrome · France.
Among the 31 studies in Antiphospholipid Syndrome with a site in France, this one has the largest planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2025, is one of 7 with no phase, reaches primary completion later than 3 of the 10 other live ones, and was the 27th registered.
121 studies on the registry are indexed under Antiphospholipid Syndrome; 52 are open to participants now.
Browse Antiphospholipid Syndrome studies →11 of the 31 studies in Antiphospholipid Syndrome with a site in France are open now. Recruiting first, the newest first:
University Hospital, Strasbourg, France · Sites in France
Ages 18–70
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+ · Healthy volunteers
Chugai Pharmaceutical · Sites in France, United States, Australia and 17 more countries
Ages 18–85
Central Hospital, Nancy, France · Sites in France
Ages 18+
Stéphane Zuily · Sites in France
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 38 Antiphospholipid Syndrome studies recruiting now, 14 (37%) set no upper age limit and 19 (50%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 41 across 65 interventional studies indexed under Antiphospholipid Syndrome.
Median enrollment 102 across the 14 interventional studies, 310 across the 17 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 31 have an industry lead sponsor. The 10 most frequent:
CHU de Reims is the lead sponsor of 276 studies on the registry; 50 are open to participants now.
CHU de Reims has 1 study filed under Antiphospholipid Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Antiphospholipid Syndrome with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06371417Chugai PharmaceuticalPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 2027-03-31 |
| NCT07178925University Hospital, RouenFollow-up Cohort of Patients With Antiphospholipid Syndrome | 2027-10-16 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Antiphospholipid Syndrome with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Stroke represents a major cause of morbidity and mortality despite significant progress in recent decades. In individuals under the age of 65, the etiologies of ischemic stroke (IS) are diverse, and management is well-established. Antiphospholipid syndrome (APS) accounts for 10 to 20% of the causes of stroke in this population. In elderly individuals, APS is not systematically investigated due to the predominance of embolic, atherosclerotic, and small vessel disease causes. However, delayed discovery of APS is not uncommon and is more frequently associated with the occurrence of arterial thrombosis. Moreover, the management of APS involves several challenges given the risk of recurrence of thrombosis and the potential association with conventional cardiovascular risk factors. The antithrombotic treatment consists of lifelong anticoagulation, excluding direct oral anticoagulants (DOACs) due to the risk of thrombotic recurrence. The main objective of the study will be to assess the prevalence of antibodies useful for the diagnosis of APS (Sapporo criteria) in individuals aged 65 or older hospitalized for an ischemic stroke (IS) or transient ischemic attack (TIA).
Furthermore, the classification of APS is likely to evolve in the coming years with the inclusion of new clinically relevant antibodies (anti-phosphatidylserine and anti-phosphatidylethanolamine) because of their strong association with the occurrence of thrombosis. Even though they are often associated with circulating anticoagulants, they are also found in 10% of APS cases negative for other antibodies.
Patient inclusion in the study should occur during the acute phase of the stroke, before the initiation of anticoagulant treatment.
Thus, after verifying the inclusion and exclusion criteria, patients will be informed and must sign the informed consent form if they agree to participate.
After inclusion, the research procedure will be as follows:
Conduct a unique immunological biological assessment with:
Clinical and biological data will be reviewed at the end of the study by two doctors (a neurologist and an internist) to confirm or exclude the APS diagnosis and its contribution to the neurological condition.
An internal medicine follow-up will be initiated for patients with confirmed APS, and an appropriate treatment will be proposed.
Stroke represents a major cause of morbidity and mortality despite significant progress in recent decades, particularly in acute-phase management. In 80% of cases, stroke is ischemic (IS), and the etiology and prognosis can vary depending on the patient's age. A comprehensive etiological workup allows for the adaptation of secondary prevention, thereby helping to reduce the risk of recurrence.
In individuals under the age of 65, etiologies of ischemic stroke (IS) are multiple, and management is well-established. In individuals under 50, antiphospholipid syndrome (APS) accounts for 10 to 20% of the causes of ischemic stroke, highlighting the importance of this etiology in younger patients. The diagnosis of IS/TIA related to APS relies on expert evaluation of clinical and biological data.
This syndrome is characterized by thrombosis in arterial or venous territories as well as the detection of specific antibodies (anti-cardiolipin antibodies, and/or anti-β2-glycoprotein type 1 antibodies, and/or circulating anticoagulants), with a cumulative risk of thrombosis depending on the number of antibodies identified. Historically, APS was associated with lupus and considered secondary, but it is now well accepted that it can occur in isolation and thus be primary.
APS is not systematically sought in elderly patients due to the predominance of cardioembolic, atherosclerotic, and small vessel disease causes. However, the late discovery of APS is not uncommon and is more frequently associated with arterial thrombosis. A retrospective study including a systematic search for APS in patients with IS found a significant association between older age and the presence of antiphospholipid antibodies (71 vs 66 years). Management presents several challenges due to the risk of recurrence of both arterial and venous thrombosis, as well as the potential association with conventional cardiovascular risk factors. Antithrombotic treatment involves lifelong anticoagulation, excluding direct oral anticoagulants (DOACs) such as Rivaroxaban due to the risk of thrombotic recurrence. A retrospective study also showed an association between APS and atrial fibrillation, reaching 30%. Atrial fibrillation, the prevalence of which increases with age, is increasingly treated with DOACs, suggesting the need to investigate APS in order to adapt the antithrombotic treatment and reduce the risk of recurrence.
Furthermore, the classification of APS is likely to evolve in the coming years with the inclusion of new clinically relevant antibodies, such as anti-phosphatidylserine and anti-phosphatidylethanolamine. These antibodies are strongly associated with the occurrence of thrombosis. Moreover, although these antibodies are strongly associated with circulating anticoagulants (which are difficult to detect due to the need for no anticoagulant treatment at the time of sample collection), they are also found in 10% of APS cases that are negative for other antibodies. With this study, we propose to systematically investigate these two antibodies as well.
Patient inclusion in the study should occur during the acute phase of the stroke, before the initiation of anticoagulant treatment.
Thus, after verifying the inclusion and exclusion criteria:
After inclusion, the research procedure will be as follows:
Conduct a unique immunological biological assessment with:
Clinical and biological data will be reviewed at the end of the study by two doctors (a neurologist and an internist) to confirm or exclude the APS diagnosis and its contribution to the neurological condition.
An internal medicine follow-up will be initiated for patients with confirmed APS, and an appropriate treatment will be proposed.
inclusion criteria :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Collectio nof blood
Collection of an additional volume of blood in the initial blood test.
Prevalence of antiphospholipid antibodies in patients aged at least 65 years hospitalized for a TIA or an ischemic stroke
Evaluate the prevalence of antibodies useful for the diagnosis of Antiphospholipid syndrome in patients aged at least 65 years hospitalized for a TIA or a stroke : anticardiolipin antibodies, anti-beta-2-glycoprotein-I lantibodies and lupus anticoagulant
Time frame: At the inclusion
Prevalence of confirmed Antiphospholipid syndrome at 12 weeks
Prevalence of confirmed Antiphospholipid syndrome according to Sapporo criteria
Time frame: At 12 weeks
Type of TIA/stroke, location and clinical manifestations
In cases of confirmed Antiphospholipid syndrome, describe the type of stroke/TIA, its location and its clinical manifestations
Time frame: At the inclusion
Prevalence of anti-phosphatidylethanolamine antibodies
Prevalence of anti-phosphatidylethanolamine antibodies
Time frame: At the inclusion
Prevalence of anti-phosphatidylserine antibodies
Prevalence of anti-phosphatidylserine antibodies
Time frame: At the inclusion
Started Sep 2025 (actual). Primary completion is estimated for Dec 2027, 27 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.